524403
Pravastatin, Sodium Salt
A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM).
別名:
(βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β,δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic Acid Na, 3β-Hydroxycompactin, Na, Pravastatin, Sodium Salt
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
Assay:
≥98% (HPLC)
Form:
crystalline solid
Storage condition:
OK to freeze, desiccated (hygroscopic)
Quality Segment
description
Merck USA index - 14, 7714
assay
≥98% (HPLC)
form
crystalline solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
color
white
solubility
water: 100 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
[Na+].[O-]C(=O)C[C@H](O)C[C@H](O)CC[C@@H]1[C@H]2[C@H](C[C@@H](C=C2C=C[C@@H]1C)O)OC(=O)[C@H](CC)C
InChI
1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1
InChI key
VWBQYTRBTXKKOG-IYNICTALSA-M
General description
A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM). Offers cardioprotection. Also acts as an immunomodulator and an inhibitor of ras p21 isoprenylation.
Biochem/physiol Actions
Cell permeable: no
Primary Target
AMG-CoA reductase
AMG-CoA reductase
Product does not compete with ATP.
Reversible: no
Target Ki: ~1 nM inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocking in vivo cholesterol synthesis
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Kwak, B., et al. 2000. Natl. Med.6, 1399.
Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci.19, 26.
Narisawa, T., et al. 1996. Jpn. J. Cancer Res.87, 798.
Cohen, L.H., et al. 1993. Biochem. Pharmacol.45, 2203.
Koga, T., et al. 1990. Biochim. Biophys. Acta.1045, 115.
Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179
Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci.19, 26.
Narisawa, T., et al. 1996. Jpn. J. Cancer Res.87, 798.
Cohen, L.H., et al. 1993. Biochem. Pharmacol.45, 2203.
Koga, T., et al. 1990. Biochim. Biophys. Acta.1045, 115.
Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Environmental Hazard (N)
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable